Could This Rare-Disease Drug Candidate Become a Blockbuster?

Could This Rare-Disease Drug Candidate Become a Blockbuster?

Source: 
Motley Fool
snippet: 
  • AstraZeneca and Ionis recently shared promising phase 3 clinical trials for eplontersen.
  • If approved, the drug candidate could top $1 billion in annual sales -- split between the two companies.
  • AstraZeneca has an array other efforts, too, that make it an excellent pick for growth investors.